Inflammation and Atherosclerosis: The End of a Controversy

Circulation. 2017 Nov 14;136(20):1875-1877. doi: 10.1161/CIRCULATIONAHA.117.030484. Epub 2017 Sep 15.

Author

Göran K Hansson¹

Affiliation

¹ Department of Medicine, Solna and Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden. goran.hansson@ki.se.

PMID: 28916641
DOI: 10.1161/CIRCULATIONAHA.117.030484

No abstract available

Keywords: atherosclerosis; atherothrombosis; clinical trial; inflammation; interleukin-1; myocardial infarction.

MeSH terms

Anti-Inflammatory Agents / adverse effects
Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Coronary Artery Disease / diagnosis
Coronary Artery Disease / drug therapy*
Coronary Artery Disease / immunology
Coronary Artery Disease / mortality
Humans
Inflammation / diagnosis
Inflammation / drug therapy*
Inflammation / immunology
Inflammation / mortality
Inflammation Mediators / antagonists & inhibitors*
Inflammation Mediators / immunology
Interleukin-1beta / antagonists & inhibitors*
Interleukin-1beta / immunology
Randomized Controlled Trials as Topic
Risk Factors
Secondary Prevention / methods*
Treatment Outcome

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
IL1B protein, human
Inflammation Mediators
Interleukin-1beta
canakinumab